Article

Not peer-reviewed version

Medications for Opioid Use Disorder (MOUD) Treatment in the Fentanyl Era: Patient, Provider, and System-Level Challenges

Omolayo T. Umaru *

Posted Date: 27 February 2026

doi: 10.20944/preprints202602.1727.v1

Keywords: fentanyl; opioid use disorder; MOUD; buprenorphine; precipitated withdrawal; treatment retention; substance use; methadone; medication-assisted treatment; harm reduction

Article

Medications for Opioid Use Disorder (MOUD) Treatment in the Fentanyl Era: Patient, Provider, and System-Level Challenges

Omolayo T. Umaru

Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, USA; umaru002@umn.edu

Abstract

Background: Medications for Opioid Use Disorder (MOUD) have historically been the cornerstone of evidence-based treatment for opioid use disorder (OUD). However, the widespread proliferation of illicit fentanyl has introduced unprecedented challenges that threaten the effectiveness of traditional MOUD approaches. **Objective**: This paper examines the multifaceted barriers to MOUD implementation and effectiveness in the context of widespread fentanyl use, organized across patient, provider, and system levels. **Methods**: This paper synthesizes current literature on fentanyl-related challenges to MOUD delivery, focusing on precipitated withdrawal, pharmacological complications, patient perceptions, and healthcare system barriers. **Key insights**: Fentanyl's unique pharmacokinetic properties- including high lipophilicity, prolonged tissue accumulation, and variable elimination rates - fundamentally disrupt standard buprenorphine induction protocols. These pharmacological challenges cascade into patient-level barriers including fear of precipitated withdrawal, treatment avoidance, and premature dropout. Provider-level barriers include clinical uncertainty, inadequate training on fentanyl-specific protocols, and challenges with individualized dosing. System-level barriers encompass regulatory constraints, access limitations, and lack of integration between emergency, inpatient, and outpatient care settings. **Conclusion**: The fentanyl era has exposed critical gaps in MOUD delivery that span multiple levels of the healthcare system. Understanding these interconnected barriers is essential for developing targeted interventions and policy reforms. Future research should focus on fentanyl pharmacokinetics, optimized induction protocols, and MOUD efficacy in poly-substance use contexts.

Keywords: fentanyl; opioid use disorder; MOUD; buprenorphine; precipitated withdrawal; treatment retention; substance use; methadone; medication-assisted treatment; harm reduction

1. Introduction

1.1. Background and Context

Opioid use disorder (OUD) remains a major public health crisis in the United States, affecting approximately 5.7 million people in 2023, with similar prevalence rates across racial groups (SAMHSA, 2024a). Medications for Opioid Use Disorder (MOUD) - primarily methadone and buprenorphine, with naltrexone as an additional option - have long represented the foundation of evidence-based treatment for this condition (Leshner & Dzau, 2019). Clinical evidence demonstrates that MOUD results in reduced illicit opioid use, lower overdose risk, higher treatment retention (Mancher & Leshner, 2019), improved abstinence and social functioning, with decreased crime and mortality (Martin et al., 2022).

However, the growing prevalence of fentanyl in the illicit drug supply has fundamentally disrupted MOUD effectiveness (Morris, 2022). Unlike heroin and prescription opioids, fentanyl's high potency and distinct pharmacokinetic profile not only undermine standard treatment protocols

 doi:10.20944/preprints202602.1727.v1

and complicate withdrawal management (Dickson-Gomez et al., 2022), but also reduce treatment retention (Cook et al., 2021), resulting in poorer outcomes (Socias et al., 2022).

1.2. Scope and Purpose

This paper examines the barriers to effective MOUD implementation in the fentanyl era, organized across three levels: patient-level barriers (including precipitated withdrawal risk, fear and misconceptions, and retention challenges), provider-level barriers (including clinical uncertainty and training gaps), and system-level barriers (including access limitations and regulatory constraints). Recent conceptual work has characterized precipitated withdrawal in the fentanyl era as a structural misalignment between established buprenorphine induction protocols and contemporary drug supply realities, rather than a failure of the medication itself (Umaru, 2026). By synthesizing current literature on these interconnected challenges, this paper aims to provide an understanding of how fentanyl has transformed the landscape of OUD treatment and identify critical gaps requiring urgent attention.

2. The Central Challenge: Precipitated Withdrawal with Fentanyl

2.1. Mechanism of Precipitated Withdrawal

Precipitated withdrawal represents the most immediate and severe barrier to buprenorphine initiation in fentanyl users. This phenomenon occurs when buprenorphine, a partial opioid agonist with high receptor affinity, displaces full agonists like fentanyl from mu-opioid receptors. The displacement reduces overall receptor activation, triggering acute withdrawal symptoms as early as 15 to 60 minutes after buprenorphine administration (College of Physicians & Surgeons of Manitoba, 2023). Notably, this effect is not observed with methadone (Varshneya et al., 2022), highlighting a specific vulnerability in buprenorphine-based approaches.

2.2. Why Fentanyl Is Different

Traditional buprenorphine induction protocols were developed for heroin and prescription opioids, which have relatively predictable clearance timelines. Unlike these traditional opioids, fentanyl users often require longer periods of abstinence before safely initiating buprenorphine. However, the heightened withdrawal symptoms during this extended waiting period make it difficult for many patients to tolerate (Varshneya et al., 2022), driving them away from treatment or back to illicit use to relieve symptoms.

Research has documented clear evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl (Varshneya et al., 2022), establishing this as a clinically significant phenomenon rather than merely a theoretical concern. This pharmacological mismatch between fentanyl's properties and standard induction protocols creates a fundamental barrier to treatment access.

3. Patient-Level Barriers

3.1. Fear and Treatment Avoidance

The risk of precipitated withdrawal has created profound fear among people who use fentanyl, with this fear spreading rapidly through community networks where stories of "getting sick from the clinic" become cautionary tales that deter others from seeking treatment (Simpson et al., 2024). A 2024 community-based study found that withdrawal experiences and their consequences significantly shape treatment-seeking behavior, with precipitated withdrawal events creating lasting psychological barriers to MOUD engagement (Simpson et al., 2024).

Many patients express concerns about "trading one addiction for another" when transitioning to buprenorphine (Dickson-Gomez et al., 2022). While clinical evidence demonstrates that when used as prescribed, buprenorphine reduces effects of physical dependency such as withdrawal symptoms

 doi:10.20944/preprints202602.1727.v1

and cravings, increases safety in cases of overdose, and blocks the euphoric effects of other opioids (SAMHSA, 2024b), these misconceptions persist and are amplified by legitimate experiences of precipitated withdrawal.

3.2. Perceptions of Medication Inadequacy

Despite being an evidence-based treatment for OUD, buprenorphine faces significant patient resistance in the fentanyl era. Some patients report that buprenorphine dosing does not adequately address the intense cravings and withdrawal symptoms associated with high fentanyl tolerance (Herring et al., 2021). Qualitative research reveals that patients in the fentanyl era report that "everything is not right anymore" with buprenorphine treatment, describing experiences of inadequate symptom relief and persistent cravings that were not characteristic of the prescription opioid era (Silverstein et al., 2019).

Additionally, the bitter taste of sublingual Suboxone (buprenorphine/naloxone) undermines adherence for some patients (Pinto et al., 2010). Current dosing protocols developed for traditional opioids may be insufficient for patients with high fentanyl tolerance, leading them to perceive the medication as ineffective and abandon treatment prematurely.

3.3. Treatment Retention Challenges

While evidence regarding differential retention between heroin/prescription opioid users and fentanyl users is mixed (Wakeman et al., 2019), research clearly demonstrates that fentanyl users face unique retention challenges. A study of patients living with HIV and OUD found significant associations between fentanyl use and difficulties with both initiating and persisting on MOUD, with fentanyl users facing distinct barriers compared to those using other opioids (Cook et al., 2021). Similarly, research in Canada showed that fentanyl use was associated with higher rates of both treatment discontinuation and failure to initiate buprenorphine/naloxone, with these effects observed even among patients with prescription-type OUD (Socias et al., 2022).

For fentanyl users, treatment retention is particularly difficult due to the intensity of cravings and the prolonged withdrawal timeline. Fentanyl's extended withdrawal period - which can last weeks or months - may cause patients to abandon treatment prematurely when symptoms persist long after medication initiation (Silverstein et al., 2019). Compared to the more immediate stabilization possible with shorter-acting opioids, the subtle and gradual stabilization with buprenorphine may feel unsatisfying initially, requiring additional support during the transition period to maintain engagement.

4. Pharmacological and Supply Chain Complications

4.1. Fentanyl's Unique Pharmacological Properties

Fentanyl is 50 times more potent than heroin and 100 times more potent than morphine (Texas Health & Human Services Commission, n.d.), creating unprecedented tolerance levels that traditional MOUD approaches were not designed to address. Several pharmacological characteristics distinguish fentanyl from traditional opioids:

Lipophilicity and Tissue Accumulation: Fentanyl is highly lipophilic, accumulating in adipose tissue and creating drug reservoirs that can require four weeks or more for complete clearance (Huhn et al., 2020). Research has documented protracted renal clearance of fentanyl in persons with OUD, with detectable levels persisting far longer than previously assumed (Huhn et al., 2020). This extended clearance makes it extremely difficult to determine when to safely initiate buprenorphine without risking precipitated withdrawal.

Individual Variability: Factors such as age, body composition, and genetics create significant differences in fentanyl elimination rates (Smith, 2009), making standardization of induction protocols

 doi:10.20944/preprints202602.1727.v1

challenging. What works for one patient may not work for another, requiring individualized approaches that are difficult to implement in standardized care settings.

Fentanyl Analogues: The rapid proliferation of fentanyl analogues further complicates treatment standardization due to varying pharmacological profiles (Pichini et al., 2018). Each analogue may have distinct potency, receptor affinity, and clearance characteristics, making clinical predictions even more uncertain.

4.2. Contamination of the Illicit Drug Supply

The widespread contamination of the illicit drug supply with fentanyl has caused inadvertent dependence even among those not intentionally seeking it (United States Drug Enforcement Administration, n.d.). This means people may be using fentanyl unknowingly, complicating clinical presentation and treatment needs. Patients who believe they are using heroin or prescription opioids may actually be using fentanyl, making their self-reports unreliable for treatment planning.

Furthermore, the adulteration of fentanyl with xylazine - a non-opioid sedative used in veterinary medicine - creates additional complications for withdrawal management. Xylazine has no reversal agent currently approved for human use (Gupta et al., 2023), meaning that even with optimal opioid treatment, patients may continue experiencing withdrawal-like symptoms from xylazine that MOUD cannot address.

4.3. Poly-Substance Use Complications

The co-use of substances like stimulants and benzodiazepines creates additional challenges through overdose amplification effects. Research has documented the co-occurrence of stimulant use with fentanyl as a driver of the "fourth wave" of the overdose crisis (Townsend et al., 2022), creating what some researchers have termed the "fourth wave" of the opioid epidemic (Maucione, 2023).

Multiple barriers emerge from poly-substance use patterns:

- **Lack of evidence-based treatments**: While MOUD effectively addresses opioid use, there are no comparable evidence-based pharmacological interventions for stimulant use disorder.
- **Symptom masking**: Co-use of stimulants or benzodiazepines can mask symptoms of opioid overdose, decreasing the likelihood of bystanders recognizing an emergency and administering naloxone.
- **Misaligned treatment-seeking**: Individuals who primarily use stimulants may not seek opioid-related harm reduction services because they do not identify as opioid users, despite fentanyl contamination in stimulant supplies (Townsend et al., 2022).

5. Provider-Level Barriers

5.1. Clinical Uncertainty and Training Gaps

Clinicians face significant challenges in managing fentanyl-exposed patients due to the unpredictable nature of fentanyl pharmacokinetics. The individual variability in fentanyl metabolism, combined with the proliferation of analogues with distinct properties, makes it difficult to predict safe induction timing for any given patient. This uncertainty can lead to provider hesitation, delayed induction, or reliance on outdated protocols that increase precipitated withdrawal risk.

Many clinicians lack adequate training on fentanyl-specific pharmacology, including understanding of fentanyl's lipophilicity, unpredictable withdrawal profile, and the impact on timing and dosing of buprenorphine (Varshneya et al., 2022). Traditional medical education and residency training programs were developed during the prescription opioid and heroin eras, leaving current practitioners unprepared for the unique challenges of the fentanyl era.

 doi:10.20944/preprints202602.1727.v1

5.2. Challenges with Protocol Individualization

Literature suggests that physicians must often deviate from standard protocols by tailoring dose size and frequency based on patient tolerance, feedback, and response to discourage premature dropout (Gautam et al., 2006). However, this individualization requires both clinical expertise and additional time - resources that may not be available in busy clinical settings.

The tension between standardized protocols (which facilitate consistent care delivery and quality assurance) and individualized approaches (which are necessary given fentanyl's variable effects) creates ongoing challenges for providers. Without clear guidance on when and how to deviate from standard protocols, clinicians may either adhere too rigidly to approaches that are no longer effective or vary their practices in ways that lack evidence basis.

5.3. Limited Integration of Harm Reduction

Harm reduction strategies - including fentanyl test strips, syringe exchange programs, naloxone distribution, and overdose prevention training - represent crucial tools for building trust and supporting treatment progress when perfect abstinence is not immediately feasible (Shah et al., 2025). However, integration of these approaches into MOUD treatment settings remains inconsistent.

Some providers may view harm reduction strategies as incompatible with medication-based treatment or may lack training in how to effectively combine these approaches. This represents a missed opportunity, as harm reduction engagement often serves as a pathway to MOUD initiation and can support retention even when patients continue some substance use during stabilization.

6. System-Level Barriers

6.1. Access and Delivery Model Constraints

Despite the documented effectiveness of MOUD, significant access barriers persist. Traditional methadone treatment requires daily clinic visits and is subject to restrictive regulations, creating barriers for patients with work schedules, transportation challenges, or who live in rural areas. While buprenorphine's office-based model provides greater flexibility, access remains limited by the geographic distribution of prescribers and the capacity of existing programs.

Recent policy changes, including the elimination of the X-waiver requirement in 2023 (LeFevre et al., 2023), have removed some regulatory barriers to buprenorphine prescribing. However, regulatory reform alone is insufficient without addressing the clinical knowledge gaps and system capacity issues that limit effective implementation.

6.2. Discontinuity of Care

Ensuring seamless transition and continuity between emergency departments, inpatient settings, and outpatient providers remains a significant challenge. Gaps in treatment during these transitions create opportunities for relapse and reduce overall retention rates (Weimer et al., 2019). Patients who initiate MOUD in emergency departments or during hospitalizations often fail to connect with ongoing outpatient care, returning to substance use without continued support.

The lack of integrated care systems means that patients must navigate complex, disconnected services at a time when they are most vulnerable. This fragmentation is particularly problematic in the fentanyl era, when the risk of precipitated withdrawal requires careful coordination and close monitoring during the critical induction period.

6.3. Limited Treatment Setting Diversity

While innovative models exist - including mobile methadone clinics (Via, 2021), telehealth options, and pharmacy-based care - these remain exceptions rather than the standard. Research suggests that flexible treatment models providing variable visit schedules, take-home doses, and

 doi:10.20944/preprints202602.1727.v1

reduced barriers to entry could support retention in populations affected by work schedules, commute distances, and transportation challenges (Monico et al., 2025).

The expansion of pharmacist roles in MOUD delivery represents a promising but underutilized opportunity. Through collaborative practice agreements, pharmacists are already administering injectable naltrexone (Ford et al., 2019) and may soon be initiating patients on buprenorphine (Green et al., 2023). Pharmacies' accessibility and extended hours could address critical access gaps (Valliant et al., 2022), but regulatory and reimbursement barriers continue to limit this model's implementation.

Proposed legislation such as the Modernizing Opioid Treatment Access Act (MOTAA) would further expand methadone access through pharmacies (Simon & Fox, n.d.), but such reforms require both policy change and system readiness to implement new models effectively.

7. Interconnections Between Barrier Levels

The barriers described across patient, provider, and system levels do not exist in isolation but rather create reinforcing cycles that compound treatment challenges. For example:

Fear-driven treatment avoidance (patient level) is amplified by **provider uncertainty** (provider level) about how to safely conduct inductions, which is itself constrained by **rigid regulatory frameworks** (system level) that limit protocol flexibility.

Precipitated withdrawal experiences (patient level) occur partly due to **inadequate provider training** (provider level) on fentanyl-specific protocols, which reflects **insufficient system investment** (system level) in updating clinical guidelines and education.

Treatment retention challenges (patient level) are exacerbated by **discontinuity of care** (system level), which providers struggle to address given **time and resource constraints** (provider level).

Understanding these interconnections is essential for developing effective interventions. Addressing barriers at only one level will likely have limited impact; comprehensive solutions require coordinated efforts across all three levels.

8. Discussion

8.1. Summary of Key Findings

This paper has identified multiple interconnected barriers to effective MOUD implementation in the fentanyl era:

1. **Pharmacological barriers**: Fentanyl's unique properties - high lipophilicity, variable metabolism, prolonged tissue accumulation, and existence of multiple analogues - fundamentally disrupt standard buprenorphine induction protocols designed for shorter-acting opioids.
2. **Patient-level barriers**: Fear of precipitated withdrawal, perceptions of medication inadequacy, and prolonged stabilization periods create psychological and practical barriers to treatment initiation and retention.
3. **Provider-level barriers**: Clinical uncertainty, inadequate training on fentanyl-specific approaches, and challenges with protocol individualization limit providers' ability to safely and effectively initiate and manage MOUD.
4. **System-level barriers**: Access limitations, discontinuity of care, regulatory constraints, and limited treatment setting diversity create structural impediments to MOUD delivery.

8.2. Implications for Practice and Policy

The barriers identified in this article have significant implications for clinical practice and health policy. First, current clinical practice guidelines for MOUD require updating to reflect the pharmacological realities of fentanyl. Guidelines must provide clear, evidence-based protocols for

 doi:10.20944/preprints202602.1727.v1

managing fentanyl-exposed patients, including alternative induction approaches that minimize precipitated withdrawal risk.

Second, provider education represents a critical intervention point. Medical schools, residency programs, and continuing medical education initiatives must incorporate fentanyl-specific content into their curricula. This education should extend beyond addiction specialists to include emergency medicine physicians, primary care providers, and other frontline clinicians who encounter patients seeking MOUD.

Third, health systems must invest in infrastructure to support more flexible, patient-centered MOUD delivery models. This includes care coordination resources, telehealth platforms, peer support integration, and mechanisms for ensuring continuity across care settings.

Finally, regulatory and policy reforms must continue beyond recent advances such as X-waiver elimination. Policies should facilitate rather than constrain innovative approaches to MOUD delivery, including expanded roles for pharmacists, mobile treatment units, and low-barrier access models.

8.3. Research Gaps and Future Directions

This paper has identified several critical gaps in the current evidence base:

Fentanyl pharmacokinetics: More research is needed on fentanyl metabolism, clearance timelines, and factors contributing to individual variability. Better understanding of these pharmacokinetic parameters could enable more precise prediction of safe buprenorphine induction timing.

Induction protocol optimization: While alternative induction approaches show promise, questions remain about optimal dosing schedules, comparative effectiveness of different methods, and which approaches work best for which patient populations.

Poly-substance use: The increasing prevalence of fentanyl-stimulant co-use requires urgent research attention. Studies should examine MOUD effectiveness in poly-substance use contexts and explore potential adjunctive treatments for stimulant use disorder.

Long-term outcomes: Most existing research focuses on acute induction and short-term retention. Longer-term studies examining sustained recovery, quality of life, and mortality outcomes in the fentanyl era would provide valuable evidence for treatment approaches.

Implementation science: Research is needed on how to effectively disseminate and implement evidence-based approaches for fentanyl-exposed populations across diverse clinical settings and health systems.

8.4. Limitations

This paper has several limitations. First, as a narrative synthesis rather than systematic review, the literature coverage is not exhaustive and may be subject to selection bias. Second, the focus on North American contexts may limit generalizability to other geographic regions with different drug supply dynamics or healthcare systems. Third, the rapidly evolving nature of the illicit drug supply means that evidence synthesized here may quickly become outdated as new fentanyl analogues or drug combinations emerge.

9. Conclusions

The proliferation of fentanyl has exposed critical limitations in traditional approaches to MOUD delivery. Barriers exist at multiple levels - the pharmacological incompatibility between fentanyl and standard buprenorphine protocols, to patient fears and misconceptions, to provider knowledge gaps, to systemic access constraints. These barriers are interconnected, creating reinforcing cycles that compound treatment challenges.

Addressing these barriers requires coordinated action across multiple fronts: updating clinical guidelines to reflect fentanyl-era realities, enhancing provider education and training, investing in flexible treatment delivery models, continuing regulatory reform, and conducting research to fill

 doi:10.20944/preprints202602.1727.v1

critical evidence gaps. The effectiveness of MOUD - and by extension, our public health response to the ongoing overdose crisis - depends on our ability to adapt these evidence-based treatments to the current pharmacological landscape.

The question is not whether MOUD remain effective interventions for OUD, but rather how quickly and comprehensively the healthcare system can adapt their delivery to meet the unique challenges of the fentanyl era. Every delay in addressing these barriers represents lives lost to a crisis that our existing tools, properly adapted, have the potential to address.

References

College of Physicians & Surgeons of Manitoba. (2023). *Introduction: The pharmacology of buprenorphine, precipitated withdrawal & management of adverse effects*. Manitoba Opioid Agonist Therapy Recommended Practice Manual. https://cpsm.mb.ca/assets/PrescribingPracticesProgram/Introduction%20Pharmacology,%20Precipitated%20Withdrawal%20&%20Management%20of%20Adverse%20Effects.pdf

Cook, R. R., Torralva, R., King, C., Lum, P. J., Tookes, H., Foot, C., Vergara-Rodriguez, P., Rodriguez, A., Fanucchi, L., Lucas, G. M., Waddell, E. N., & Korthuis, P. T. (2021). Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. *Drug and Alcohol Dependence, 228*, 109077. https://doi.org/10.1016/j.drugalcdep.2021.109077

Dickson-Gomez, J., Spector, A., Weeks, M., Galletly, C., McDonald, M., & Green Montaque, H. D. (2022). "You're not supposed to be on it forever": Medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids. *Substance Abuse: Research and Treatment, 16*, 11782218221103859. https://doi.org/10.1177/11782218221103859

Ford, J. H., Gilson, A., & Mott, D. A. (2019). Systematic analysis of the service process and the legislative and regulatory environment for a pharmacist-provided naltrexone injection service in Wisconsin. *Pharmacy, 7*(2), 59.

Gautam, S., Gupta, I. D., Nijhawan, A., & Gaur, V. (2006). *Clinical practice guidelines for management of opioid dependence*. Indian Psychiatric Society Treatment Guidelines. https://d1wqtxts1xzle7.cloudfront.net/8465795/cpg-mgmt_10-libre.pdf

Green, T. C., Serafinski, R., Clark, S. A., Rich, J. D., & Bratberg, J. (2023). Physician-delegated unobserved induction with buprenorphine in pharmacies. *New England Journal of Medicine, 388*(2), 185-186. https://doi.org/10.1056/NEJMc2208055

Gupta, R., Holtgrave, D. R., & Ashburn, M. A. (2023). Xylazine—medical and public health imperatives. *New England Journal of Medicine, 388*(24), 2209-2212. https://doi.org/10.1056/NEJMp2303120

Herring, A. A., Vosooghi, A. A., Luftig, J., Anderson, E. S., Zhao, X., Dziura, J., ... & D'Onofrio, G. (2021). High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. *JAMA Network Open, 4*(7), e2117128. https://doi.org/10.1001/jamanetworkopen.2021.17128

Huhn, A. S., Hobelmann, J. G., Oyler, G. A., & Strain, E. C. (2020). Protracted renal clearance of fentanyl in persons with opioid use disorder. *Drug and Alcohol Dependence, 214*, 108147. https://doi.org/10.1016/j.drugalcdep.2020.108147

LeFevre, N., Louis, J. S., Worringer, E., Younkin, M., Stahl, N., & Sorcinelli, M. (2023). The end of the X-Waiver: Excitement, apprehension, and opportunity. *The Journal of the American Board of Family Medicine, 36*(5), 867-872. https://doi.org/10.3122/jabfm.2023.230048R1

Leshner, A. I., & Dzau, V. J. (2019). Medication-based treatment to address opioid use disorder. *JAMA, 321*(21), 2071-2072. https://doi.org/10.1001/jama.2019.5523

Mancher, M., & Leshner, A. I. (Eds.). (2019). *Medications for opioid use disorder save lives*. National Academies Press.

Martin, E., Maher, H., McKeon, G., Patterson, S., Blake, J., & Chen, K. Y. (2022). Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health. *Journal of Substance Abuse Treatment, 139*, 108776. https://doi.org/10.1016/j.jsat.2022.108776

 doi:10.20944/preprints202602.1727.v1

Maucione, S. (2023). *Fentanyl mixed with cocaine or meth is driving the 'fourth wave' of the overdose crisis*. NPR. https://www.npr.org/sections/health-shots/2023/09/14/1199396794/fentanyl-mixed-with-cocaine-or-meth-is-driving-the-4th-wave-of-the-overdose-cris

Monico, L. B., Eastlick, M., Michero, D., Pielsticker, P., & Glasner, S. (2025). Overcoming barriers to traditional care delivery and pharmacy challenges: A qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder. *Substance Abuse Treatment, Prevention, and Policy, 20*(1), 8. https://doi.org/10.1186/s13011-024-00631-9

Morris, N. P. (2022). Opioid use disorder treatment in the age of fentanyl. *JAMA Internal Medicine, 182*(3), 249-250. https://doi.org/10.1001/jamainternmed.2021.8114

Pichini, S., Solimini, R., Berretta, P., Pacifici, R., & Busardò, F. P. (2018). Acute intoxications and fatalities from illicit fentanyl and analogues: An update. *Therapeutic Drug Monitoring, 40*(1), 38-51. https://doi.org/10.1097/FTD.0000000000000465

Pinto, H., Maskrey, V., Swift, L., Rumball, D., Wagle, A., & Holland, R. (2010). The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. *Journal of Substance Abuse Treatment, 39*(4), 340-352. https://doi.org/10.1016/j.jsat.2010.07.009

Shah, R. V., Shay, J., & Komaromy, M. (2025). Harm reduction strategies for people who use drugs. *JAMA, 333*(2), 161-162. https://doi.org/10.1001/jama.2024.23605

Silverstein, S. M., Daniulaityte, R., Martins, S. S., Miller, S. C., & Carlson, R. G. (2019). "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl. *International Journal of Drug Policy, 74*, 76-83. https://doi.org/10.1016/j.drugpo.2019.09.003

Simon, R., & Fox, A. D. (n.d.). *Improving access to methadone treatment in the US*. New York Society of Addiction Medicine. https://nysam-asam.org/access-to-care/improving-access-to-methadone-treatment-in-the-us/

Simpson, K. A., Bolshakova, M., Kirkpatrick, M. G., Davis, J. P., Cho, J., Barrington-Trimis, J., ... & Bluthenthal, R. N. (2024). Characterizing opioid withdrawal experiences and consequences among a community sample of people who use opioids. *Substance Use & Misuse, 59*(6), 886-894. https://doi.org/10.1080/10826084.2024.2306221

Smith, H. S. (2009). Opioid metabolism. *Mayo Clinic Proceedings, 84*(7), 613-624. https://doi.org/10.4065/84.7.613

Socias, M. E., Wood, E., Le Foll, B., Lim, R., Choi, J. C., Mok, W. Y., Bruneau, J., Rehm, J., Wild, T. C., Bozinoff, N., Hassan, A., Jutras-Aswad, D., & OPTIMA Research Group. (2022). Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Secondary analysis of a Canadian treatment trial. *Addiction, 117*(10), 2662-2672. https://doi.org/10.1111/add.15954

Substance Abuse and Mental Health Services Administration. (2024a). *Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health* (HHS Publication No. PEP24-07-021, NSDUH Series H-59). https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report

Substance Abuse and Mental Health Services Administration. (2024b). *Substance use: Buprenorphine*. https://www.samhsa.gov/substance-use/treatment/options/buprenorphine

Texas Health & Human Services Commission. (n.d.). *Fentanyl: One pill kills*. https://www.hhs.texas.gov/services/mental-health-substance-use/mental-health-substance-use-resources/fentanyl-one-pill-kills

Townsend, T., Kline, D., Rivera-Aguirre, A., Bunting, A. M., Mauro, P. M., Marshall, B. D., ... & Cerdá, M. (2022). Racial/ethnic and geographic trends in combined stimulant/opioid overdoses, 2007-2019. *American Journal of Epidemiology, 191*(4), 599-612. https://doi.org/10.1093/aje/kwab290

Umaru, O. T. (2026). *The fentanyl–buprenorphine paradox: Why gold standard treatment may fail in clinical practice*. SSRN. https://ssrn.com/abstract=6217139

United States Drug Enforcement Administration. (n.d.). *Facts about fentanyl*. https://www.dea.gov/resources/facts-about-fentanyl

Valliant, S. N., Burbage, S. C., Pathak, S., & Urick, B. Y. (2022). Pharmacists as accessible health care providers: Quantifying the opportunity. *Journal of Managed Care & Specialty Pharmacy, 28*(1), 85-90. https://doi.org/10.18553/jmcp.2022.28.1.85

 doi:10.20944/preprints202602.1727.v1

Varshneya, N. B., Thakrar, A. P., Hobelmann, J. G., Dunn, K. E., & Huhn, A. S. (2022). Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. *Journal of Addiction Medicine, 16*(4), e265-e268. https://doi.org/10.1097/ADM.0000000000000922

Via, L. E. (2021). Mobile methadone clinics: A necessary step in fighting the opioid epidemic. *University of Richmond Law Review, 55*(4), 61-102. https://scholarship.richmond.edu/lawreview/vol55/iss4/3

Wakeman, S. E., Chang, Y., Regan, S., Yu, L., Flood, J., Metlay, J., & Rigotti, N. (2019). Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. *Journal of Addiction Medicine, 13*(4), 253-257. https://doi.org/10.1097/ADM.0000000000000486

Weimer, M., Morford, K., & Donroe, J. (2019). Treatment of opioid use disorder in the acute hospital setting: A critical review of the literature (2014-2019). *Current Addiction Reports, 6*, 339-354. https://doi.org/10.1007/s40429-019-00267-x